Global Bio-logistics: Shifting Demands, Opportunities, and Upcoming Innovations
Introduction
Temperature-controlled logistics play a crucial role in the global, decentralised, and complex landscape of clinical trials. In this environment, products tolerate minimal error. For instance, researchers cannot remanufacture autologous cell therapy doses on demand. Moreover, a biospecimen that spends even a few hours outside its validated range can invalidate a patient’s visit and affect the entire cohort. In 2024, the WHO recorded 27,172 newly registered trials in the Western Pacific, compared to only 1,049 in Africa. This disparity, therefore, highlights significant differences in capacity and resource allocation across regions.
Delays in clinical trials are becoming increasingly costly. According to Deloitte’s analysis, the average cost of bringing a biopharma asset from discovery to launch has risen to US$2.23 billion, up from US$2.12 billion the previous year. Additionally, Phase III cycle times have lengthened by 12%. Consequently, substantial funds now support trials for assets that ultimately terminate. Although forecast returns have improved to 5.9%, they depend on a limited number of high-value assets. Thus, every avoidable delay becomes more expensive.
Execution now serves as the primary constraint on trial progress. In the UK, 97% of studies received regulatory approval within the 60-day target; however, only 27% opened recruitment in that same timeframe. Furthermore, while trial initiations rose by 36% in 2024, recruitment for industry interventional trials fell to its lowest level since 2017/18. These trends, therefore, indicate challenges in the delivery layer of clinical research.
Cell and gene therapies concentrate risks into single shipments, requiring strict compliance due to their intricate logistics. In addition, these products often travel in cryogenic dry-vapour shippers with finite hold times. Their schedules depend on a patient’s conditioning regimen rather than a laboratory calendar. Regulatory bodies like the MHRA, EMA, and FDA now emphasise documentation, temperature records, and compliance with standard operating procedures. As a result, a logistics provider’s quality system has become a crucial part of the sponsor’s audit risk. Ultimately, effective temperature-controlled logistics are vital for ensuring the integrity and success of clinical trials in this evolving landscape.
Read our full Whitepaper by emailing us at lifesciences@royaleinternational.com.
About Royale International Life Sciences
Royale International specialises in shipping high-value, temperature-controlled products. Our commitment to excellence is reflected in our quality-driven and compliant logistics procedures throughout every shipment. The Life Sciences Division manages a wide range of biological shipments across various sectors. These include CGT, R&D, pre-clinical, and clinical trials, laboratory logistics, pharmaceuticals, and biotechnology. Our Industry Experts provide tailored logistics solutions through dedicated On-Board Couriers and Express Air Freight services. Royale’s bio-logistics are accredited under our global Quality Management System (QMS) with validated equipment, trained professionals, and standardised operating procedures. All our processes are accredited by GDP, ISO, and IATA guidelines.